A phase 3, randomized, parallel-group trial showcased the efficacy of internet-based cognitive behavioral therapy (iCBT) for combatting depressive symptoms brought on by multiple sclerosis (MS).
An internet-based cognitive behavioral therapy (iCBT) program showed promise in mitigating the effects of depression experienced by patients with multiple sclerosis (MS), according to a recent study published in The Lancet Digital Health.
Individuals enduring neurological and inflammatory disorders are far more vulnerable to depression compared with the general population. Among patients with MS, depression is one of the most prevalent comorbidities and contributes to worsened disease progression, quality of life, and risk of morbidity and mortality. Notably, as the current authors mention, depression may even be an initial indication of MS.
CBT has demonstrated continual benefits in previous studies for individuals with depression; however, treatment options and therapists geared toward the needs of patients with MS—even remotely—are limited. Furthermore, fatigue and other impairments brought about by MS create additional obstacles for patients seeking these services.
Currently, there are few large-scale trials targeted toward MS-linked depression treatments. Considering this discrepancy and the barriers MS patients face with accessing adequate care, researchers set out to investigate the effectiveness of an MS-specific iCBT program for mitigating depressive symptoms in this patient population.
Participants were recruited from 5 outpatient MS care units throughout academic centers in the United States and Germany. Eligible patients were randomized 1:1:1 to stand-alone iCBT, therapist-guided iCBT, or a control that was offered access to the iCBT after 6 months. Depression severity was measured with the Beck Depression Inventory-II (BDI-II).
In total, 228 patients were included in the results. At baseline, the Patient-Determined Disease Steps (PDSS) and Expanded Disability Status Scale (EDSS) scoring indicated moderate levels of disability in participants. The iCBT groups used the program for an average of 11 days over the study period; the guided group demonstrated a higher number of logged hours (9.8 vs 7.5) and modules (9.2 vs 6.9) used during this time.
Both iCBT groups showcased significantly improved reductions in depressive symptoms compared with controls (BDI-II mean differences, control vs stand-alone: 6.32 points; P < .0001; control vs therapist guided: 5.80 points; P < .0001). The authors noted that overall quality of life improvements were also observed in the iCBT groups (measured with WHO Quality of Life-Brief Version and Multiple Sclerosis Impact Scale-29 assessments on psychological, physical, and environmental domains).
The researchers’ findings suggest that their iCBT tool is both effective and safe for treating patients with MS. Due to the improvements witnessed in both groups, as well as the remote nature of their program, they were successfully able to widen the scope of available, MS-specific treatment while addressing common hurdles (such as therapist availability or physical impairments) that bar these patients from accessing care.
Reference
Gold SM, Friede R, Meyer B, et al. Internet-delivered cognitive behavioural therapy programme to reduce depressive symptoms in patients with multiple sclerosis: a multicentre, randomised, controlled, phase 3 trial. Lancet Digit Health. 2023 Oct;5(10):e668-e678. doi:10.1016/S2589-7500(23)00109-7
Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases
May 21st 2024Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases
May 21st 2024Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
2 Commerce Drive
Cranbury, NJ 08512